A study found that the diabetes drug exenatide, similar to weight-loss medications like Ozempic, showed no benefits for Parkinson’s disease patients after 96 weeks of treatment. The trial involved over 190 participants, with half receiving exenatide and the other half a placebo. The negative results disappointed the research community and patients, although further research may explore potential benefits for specific subgroups. Teljes cikk (Euronews.com)